| Literature DB >> 26529093 |
Daniela Bezemer1, Anne Cori2, Oliver Ratmann2, Ard van Sighem1, Hillegonda S Hermanides3, Bas E Dutilh4, Luuk Gras1, Nuno Rodrigues Faria5, Rob van den Hengel1, Ashley J Duits3, Peter Reiss6, Frank de Wolf2, Christophe Fraser2.
Abstract
BACKGROUND: The HIV-1 subtype B epidemic amongst men who have sex with men (MSM) is resurgent in many countries despite the widespread use of effective combination antiretroviral therapy (cART). In this combined mathematical and phylogenetic study of observational data, we aimed to find out the extent to which the resurgent epidemic is the result of newly introduced strains or of growth of already circulating strains. METHODS ANDEntities:
Mesh:
Year: 2015 PMID: 26529093 PMCID: PMC4631366 DOI: 10.1371/journal.pmed.1001898
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Flow diagram describing the methods and underlying assumptions.
Patient baseline information.
| Characteristic | All HIV-1-Infected Patients | Patients with HIV-1 Non-B Subtype | Patients with HIV-1 Subtype B | ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||
|
| 19,095 | 1,737 | 5,852 | 4,288 | 207 | 849 | 219 |
|
| |||||||
| MSM | 10,465 (55%) | 249 (14%) | 4,340 (74%) | 4,288 | — | — | 52 (24%) |
| HT | 6,258 (33%) | 1,228 (71%) | 996 (17%) | — | — | 849 | 147 (67%) |
| HT–male | 2,760 | 488 (28%) | 526 (9%) | — | — | 447 | 79 (36%) |
| HT–female | 3,498 | 740 (43%) | 470 (8%) | — | — | 402 | 68 (31%) |
| PWID | 736 | 22 | 207 (4%) | — | 207 | — | 0 |
| Other and unknown | 1,636 | 238 | 309 (5%) | — | — | — | 20 (9%) |
|
| 36 (IQR 29–43) | 32 (IQR 26–40) | 37 (IQR 30–44) | 37 (IQR 30–43) | 32 (IQR 27–39) | 34 (IQR 28–44) | 38 (IQR 29–46) |
|
| 328 (IQR 130–530) ( | 284 (IQR 110–480) ( | 370 (IQR 186–560) ( | 390 (IQR 210–570) ( | 430 (IQR 190–670) ( | 291 (IQR 80–511) ( | 307 (IQR 101–449) ( |
|
| 2002 (IQR 1997–2007) | 2004 (IQR 2001–2007) | 2004 (IQR 1997–2007) | 2005 (IQR 1998–2008) | 1994 (IQR 1990–1997) | 2004 (IQR 1999–2007) | 2002 (IQR 1998–2005) |
|
| 1980–2011 | 1981–2010 | 1981–2010 | 1981–2010 | 1982–2010 | 1985–2010 | 1984–2010 |
|
| — | 2006 (IQR 2003–2008) | 2006 (IQR 2003–2008) | 2006 (IQR 2003–2008) | 2002 (IQR 1997–2005) | 2006 (IQR 2003–2008) | 2005 (IQR 2004–2009) |
|
| — | 1991–2011 | 1986–2011 | 1986–2011 | 1987–2010 | 1996–2011 | 1999–2011 |
|
| |||||||
| All patients | — | — | 30% (10%, 12%, 24%) | 28% (9%, 11%, 23%) | 41% (13%, 15%, 37%) | 32% (10%, 16%, 26%) | 33% (15%, 10%, 29%) |
| Treatment-naive patients | — | — | 12% (2%, 5%, 7%) ( | 12% (2%, 4%, 7%) ( | 8% (2%, 3%, 2%) ( | 11% (2%, 6%, 5%) ( | 4% (1%, 1%, 3%) ( |
| Patients with recent infection | — | — | 12% (2%, 4%, 7%) ( | 12% (2%, 4%, 7%) ( | 10% (0%, 5%, 5%) ( | 13% (3%, 4%, 6%) ( | 0% ( |
|
| |||||||
| Netherlands | 10,377 (54%) | 442 (25%) | 3,914 (67%) | 3,168 (74%) | 119 (57%) | 436 (51%) | 6 (3%) |
| Former Dutch Antilles | 1,236 (6%) | 16 (1%) | 366 (6%) | 105 | 2 (1%) | 79 (9%) | 166 (76%) |
| Suriname | 805 (4%) | 22 (1%) | 313 (5%) | 125 (3%) | 4 (2%) | 159 (19%) | 3 (1%) |
| Latin America | 652 (3%) | 17 (1%) | 274 (5%) | 179 (4%) | - | 43 (5%) | 42 (19%) |
| Western Europe | 1,228 (6%) | 36 (2%) | 400 (7%) | 313 (7%) | 32 (15%) | 37 (4%) | — |
| Central Europe | 335 (2%) | 15 (1%) | 118 (2%) | 73 (2%) | 7 (3%) | 27 (3%) | — |
| Eastern Europe | 114 (1%) | 21 (1%) | 31 | 23 | 1 | 5 | — |
| North America | 264 (1%) | 3 | 94 | 79 | 4 (2%) | 2 | — |
| North Africa and Middle East | 235 (1%) | 13 (1%) | 74 | 31 | 7 (3%) | 3 | — |
| Oceania | 66 | 7 | 19 | 18 | — | — | — |
| Sub-Saharan Africa | 3,040 (16%) | 1,063 (61%) | 55 | 36 | 1 | 16 (2%) | — |
| South and Southeast Asia | 590 (3%) | 76 (4%) | 120 | 95 | 4 | 17 (2%) | — |
| Australia | 37 | 2 | 10 | 10 | — | — | — |
| Unknown | 139 | 3 | 82 (1%) | 51 (1%) | 26 (12%) | 3 | 2 |
|
| |||||||
| Netherlands | 10,223 (70%) | 398 (33%) | 3,918 (86%) | 3,118 (91%) | 141 (88%) | 507 (79%) | 8 (6%) |
| Former Dutch Antilles | 537 (4%) | 4 | 170 (4%) | 17 | 1 | 36 (6%) | 110 (83%) |
| US | 179 (1%) | 1 | 60 (1%) | 51 (1%) | 1 | 2 | — |
| Suriname | 146 (1%) | 1 | 40 (1%) | 7 | — | 27 (4%) | — |
| Other | 3,547 (24%) | 804 (67%) | 343 (8%) | 223 (7%) | 17 (11 | 66 (10%) | 14 (11%) |
| Unknown | 4,463 | 529 | 1,321 | 872 | 47 | 211 | 87 |
|
| |||||||
| Curaçao | 700 (4%) | 5 | 219 (4%) | — | — | — | 219 |
| Amsterdam | 7,424 (39%) | 712 (41%) | 2,879 (51%) | 2,201 (51%) | 124 (60%) | 414 (49%) | — |
|
| — | — | 3,716 (52%) | 2,196 (51%) | 153 (74%) | 474 (56%) | 103 (47%) |
HT, heterosexual transmission; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protein inhibitor.
Fig 2Large transmission clusters over time: risk group of infection.
The picture illustrates the distribution of 106 large transmission clusters, where every horizontal line of dots represents one cluster, and each dot represents a single patient in the cluster by the year of diagnosis. The dots in a cluster represent in total 52% (3,061) of 5,852 ATHENA patients with a HIV-1 subtype B pol sequence in this study. The clusters are ordered by majority risk group and by the number of years between the first and last patient identified within each particular cluster. The color of each dot represents the self-reported risk group of infection. X’s indicate the estimated time of the MRCA, in orange for Curaçao. Some discrepancies may arise as the earliest cases sometimes are included with a sequence many years after their year of diagnosis. On the right-hand side the estimated mean reproduction number over the last 5 y is indicated. At the bottom of the figure, patients are represented who could not be identified as belonging to a cluster. The group above this one shows those patients who belonged to clusters in the phylogenetic tree with fewer than 10 ATHENA sequences included, which were not regarded as large clusters according to our definition. S8 Fig shows the same figure with also these smaller clusters stratified by duration. HT, heterosexual transmission.
Fig 3Large transmission clusters over time: region of origin.
As in Fig 2, but here the color of each dot represents the region of origin. In large MSM-majority clusters 79% (1,673) of MSM were of Dutch origin. HT, heterosexual transmission.
Fig 4Diagnosis and growth of transmission clusters over time.
Cluster types within the phylogenetic tree are defined as follows. Singletons (in blue) are clusters of size 1, or cases whose sequence solely clustered with sequences from the Los Alamos HIV Sequence Database. Small clusters (in green) comprise sequences from 2–9 ATHENA patients. Large clusters comprise sequences from ten or more patients in the ATHENA cohort. Amongst those, non-MSM-dominant clusters (in brown) contain a majority of sequences from non-MSM patients, whilst MSM-majority clusters contain a majority of sequences from MSM patients. Among large MSM-majority clusters, pre-1996 clusters (in dark orange) are defined as those in which the first diagnosed patient in the cluster was diagnosed before 1996, and post-1996 clusters are defined as those in which all patients in the cluster were diagnosed in or after 1996. Large MSM-majority post-1996 clusters are stratified as “time of MRCA pre-1996” (in light orange) when the estimated time of the MRCA is before 1996, and “time of MRCA post-1996” (in purple) when the estimated time of the MRCA is in or after 1996. (A) Number of MSM registered in the ATHENA cohort in the Netherlands with a sequence in this study by year of diagnosis and by cluster type. (B) Number of clusters of each type by year of first diagnosed case in each cluster.
Fig 5Large transmission clusters over time: recent infections.
As in Fig 2, but here red dots represent patients with a documented recent infection. HT, heterosexual transmission.
Fig 6Estimated case reproduction number over time for all MSM-majority transmission clusters of ≥10 cases.
The solid lines show the mean R estimate for each transmission cluster. The bold black line is the mean R of all clusters, with the 95% confidence interval shown by the dotted lines. The shaded areas show the 95% confidence intervals for each transmission cluster: darker areas indicate overlapping intervals across different transmission clusters. Transmission clusters are shown in red if their first sequence appeared before 1991, in blue if their first sequence appeared between 1991 and 2000, and in green if their first diagnosed case appeared after 2000. The black horizontal dotted line represents the threshold value R = 1. (A) Main analysis. (B) Sensitivity analysis for a looser cluster definition. (C) Sensitivity analysis for a more stringent cluster definition. (D) Sensitivity analysis for the clusters defined under a single linkage branch length threshold.
Fig 7Proportional contribution of new HIV-1 diagnoses amongst all MSM in the ATHENA cohort by decade of birth.